

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST MARCH 2021
FOR
LEUKAEMIA BUSTERS**

Azets
Carnac Place
Cams Hall Estate
Fareham
Hampshire
PO16 8UY

LEUKAEMIA BUSTERS
CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST MARCH 2021

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance Sheet	8
Notes to the Financial Statements	9 to 14

LEUKAEMIA BUSTERS
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2021

The trustees present their report with the financial statements of the charity for the year ended 31st March 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

Objectives and aims

Leukaemia Busters was established as a Charitable Incorporated Organisation (CIO) formed under a constitution dated 21st May 2014. The objectives of the charity are to relieve patients with leukaemia, lymphoma and other blood-related cancers through funding the pursuit of pure and translational scientific research aimed at the development of new improved therapies for these malignant diseases. The objective is achieved through research conducted in our dedicated research laboratory, The Simon Flavell Leukaemia Research Laboratory based at Southampton General Hospital. The charity's vision is a world in which leukaemia and related conditions are safely, quickly and completely cured and our mission is to fund and conduct research focused on providing antibody-based treatments that will provide this for leukaemia patients.

The Trustees have considered the Charity Commission's latest general guidance on public benefit when reviewing our aims and objectives and planning future activities and are satisfied that our main research activities meet requirements.

We pursue a research portfolio that has a translational value; that is research that is intended to yield practical benefits for patients through the development of novel treatments based on antibodies or other similar molecules. Unlike many medical research charities Leukaemia Busters raises funds for direct application by its own scientists in its own laboratory in Southampton, and for collaborations with major national and overseas institutions under the management of the charity's scientific directors. In this way we have been able to hold firm to on-going investment in promising lines of research that meet our core objectives without our research having to compete for grant awards from external bodies whilst still maintaining scientific excellence through exhaustive independent peer review of our publications and scientific work.

Research activities

During the reporting period the coronavirus pandemic has had a major negative impact on our research activities. Our research laboratories at Southampton General Hospital were wholly or partially closed for a significant part of the reporting period due to the various lockdowns. Furthermore there was a dramatic reduction in donated income to the charity as fundraising events run by ourselves or others were cancelled or postponed. Consequent to this the charity took advantage of the UK governments furlough scheme and were able to support the laboratory staff through this scheme during such a lean time. As the year progressed our laboratories partially opened and lab staff slowly returned to part time working and work once again got underway but at a level lower than would normally be expected.

Whilst donated income to the charity has taken a significant fall we have been fortunate to receive two legacies during the period that will help make a positive difference to the charity's financial position and the research work we undertake in the future.

A very important aspect of the charity's research activities is to publish the results of work we conduct. The various lockdown periods allowed us to take stock of some of our previous unpublished work and two new original papers were produced and published in peer reviewed international science journals:-

Smith, Wendy S., Johnston, David A., Wensley, Harrison, Holmes, Suzanne E., Flavell, Sopsamorn U., Flavell, David J. (2020).

The Role of Cholesterol on Triterpenoid Saponin-Induced Endolysosomal Escape of a Saporin-Based Immunotoxin
International Journal of Molecular Sciences 21 8734.

Wensley, H.J. Smith, W.S. Holmes, S.E. Flavell, S.U. Flavell, D. J. (2021).

The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells. Biomedicines 9, 300.

Both original papers were published as "free access" papers under a Common Public Attribution Licence and we would like to thank the sponsors (Frampton Estates Ltd and Bonhomie United Charity Society) who made this financially possible. This ensures that the papers reach the widest audience possible, subscription free and therefore at no cost to the reader. This opens up their general availability to other scientists worldwide.

LEUKAEMIA BUSTERS
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2021

The ultimate objective of our ongoing research projects is to use our experimental findings on the mechanisms involved in immunotoxin augmentation by saponins to enable us to devise better selectively targeted treatments that can be applied clinically for the direct benefit of future patients. It is vital to be able to understand the mechanisms behind augmentation in order to be able to exploit such findings to the design of immunotoxin (and other) therapies that deliver maximal efficacy with minimal side effects. We continue to look for new initiatives and alternative methods to improve treatments for leukaemia and lymphoma, exploiting those which we consider the most promising and achievable within the limits of our available resources.

As clearly stated in trustees annual reports from previous years, an important aspect of the charity's activities is the development of young scientists who will eventually go on to conduct their own independent research in future years. To this end the charity has always in the past favoured supporting PhD scholarships in our own laboratories for candidates to conduct laboratory-based research that is relevant to the charity's research objectives. In the past the charity has taken a leading role in the training of young cancer research scientists up to PhD level and recognises that this forms an important contribution to help nurture the next generation of talented and successful research scientists. The trustees are currently reviewing how best to most efficiently promote this important aspect of the charity's activities for future years.

ACHIEVEMENT AND PERFORMANCE

Charitable activities

The Trustees are committed to the running of the CIO with extremely low overhead costs. The charity does not employ expensive fundraisers but instead relies on voluntary and community efforts to raise funds. The Trustees continue to improve and refine, where necessary, good governance practices without adding an unnecessary burden to operating costs. The trustees remain confident that income streams will increase once the COVID-19 pandemic subsides and will make particular use of social networking and internet-based technologies to achieve this.

The Trustees continue to maintain robust and reliable financial management systems that adhere to current regulations which have proven successful in the past. The CIO has a clear sense of both purpose and direction that is driven by positive outcomes in the research it funds that is viewed as an important incremental step towards clinical benefits for patients. The CIO retains a small but strong group of dedicated Trustees who between them share a good range of skills including scientific, business and management. As a charity funding medical research with responsibility for on-going laboratory and staffing costs we have an obligation to remain financially sound and prudent. Our management systems are transparent and Trustees exercise effective controls over money and assets.

We strongly believe that as an established local charity our clearly stated aims, well publicised achievements and prudent financial management have been the hallmarks of our success. The resultant low administrative overheads that we incur will allow us to truthfully tell organisations and individuals that ninety six pence of every pound donated goes directly towards our charitable objectives. Maintaining our low running costs is absolutely essential if we are to project the right ethos to staff, beneficiaries and the wider public.

The Trustees are mindful of the charity's exposure to risk and have put in place checks and balances designed to minimise these. The Trustees are aware that important EU rules governing data protection termed the General Data Protection Regulation (GDPR) came into effect in the UK on the 25th May 2018 and are now directly affecting the way in which the charity stores and uses personal data for fundraising purposes. The charity has always treated the personal data it stores securely with absolute confidentiality and has never shared this data with any third party or used it in ways that might be viewed as unethical.

The scientific research objectives of the charity are clearly stated. Laboratory-based research work streams are carefully costed before commencement to ensure that we operate within the bounds of affordability. Increasing efforts will be made to attract funding from other charitable trusts, supportive academic institutions, government or other international sources. The majority of our funding to date has come from charitable trusts, charitable donations from individuals, other charitable organisations or legacies and we will continue to build on these.

Our financial reporting is detailed, scrutinised and approved by the Board of Trustees. *Pro bono* support of our financial reporting is openly offered by Azets (formerly Wilkins Kennedy), our accountants and by our bankers HSBC, Virgin Money and NatWest which allows us to use our funds more effectively for the purpose for which they were intended. The Trustees are enormously grateful to these organisations for their generosity in offering their free services to the charity.

The professional contributions to the charity's fully qualified postgraduate and postdoctoral scientific research staff cannot be understated and are absolutely vital to the success of the charity's stated objectives. The trustees intend to safeguard

LEUKAEMIA BUSTERS
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2021

these scientific posts recognising that they are central to achieving the charity's set objectives. All contracts of employment and salary scales for the science staff are drawn up to closely parallel those offered to University of Southampton employees. This helps ensure that we remain competitive for and retain high quality research staff. All our scientific staff are now enrolled on a workplace pension scheme run by the government approved "Smart Pension", identified and selected by the Trustees as being best in terms of online operative simplicity and benefits offered to pension holders. Laboratory operating and consumables costs are scrutinised, reconciled and allocated at each Board of Trustees meeting. Larger items of equipment are purchased using a 'best value' procedure that entails obtaining a minimum of three quotations and selecting that which offers best value for money.

The charity's Trustees recognise the growing importance of legacies to our funding and see this as a priority for the future financial health of the charity. The Trustees are enormously grateful to those kind individuals who consider leaving the charity a legacy in their will. Indeed the Trustees are very grateful to all those loyal supporters, past and present, who have unstintingly supported the Leukaemia Busters over the past 29 years and hope that they will be able to continue to do so in the future to keep our work alive. It is these individuals who have made possible the lifesaving work we have conducted in the past. The Trustees are optimistic that improving economic forecasts will ensure that future funding levels will safeguard the charity's work in the development of new and improved treatments for leukaemia and other blood cancers.

FINANCIAL REVIEW

Investment policy and objectives

In accordance with the CIO constitution the Trustees have the power to invest in any investments as they see fit to further the objectives of the CIO. The current policy is to adopt a low risk investment strategy based on maximising income from bank deposits.

Financial position

During the year ended 31 March 2021 the CIO received donations and legacies totalling £273,884. The total fund balance at the end of the year amounted to £427,474.

The Trustees confirm that the CIO's assets are available and adequate to fulfil its obligations to meet all existing commitments.

Reserves Policy

The Trustees adopt a reserves policy of maintaining sufficient funds to meet the costs of approved research projects, and to build funds in expectation of needing to fund clinical trial-related work in the future. Nonetheless the CIO seeks to establish break clauses in its grant approvals as a matter of prudence to ensure that the charity is not overextended.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document (a constitution) that constitutes a charitable incorporated organisation (CIO).

Governance position

The trustees continue to retain and improve, where necessary, good governance practices without adding an unnecessary burden to operating costs.

Recruitment and appointment of new trustees

All trustees undergo a common selection and induction process. The trustees have highlighted key areas of experience and competency that the trustee group needs to contain. To function effectively the board needs to have diverse skills covering: Business & Governance; Marketing & Media; Scientific & Medical. All new recruited trustees undergo the same application, selection and induction process, to make sure all are fit for purpose, and can make a positive contribution to the charity.

Organisational structure

The board of five trustees provide the steerage and financial control of the charity with the day to day management delegated to the Charity & Scientific Director Dr D J Flavell. Executive Scientific Director Dr S U Flavell together with Dr D J Flavell is responsible for the effective management of the science programmes of the charity through a combination of administrative and scientific skills. A well developed and clearly defined reporting system for the scientific directors to the Trustees has been developed over the years to protect all aspects the charity's position and ensure good governance and best practice. The trustees have set objectives to continue to improve systems and processes in line with market best practice, and the board has formally adopted the "Code of Good Governance" principles.

LEUKAEMIA BUSTERS
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2021

STRUCTURE, GOVERNANCE AND MANAGEMENT

Induction and training of new trustees

All potential new trustees are required to complete a standard application form detailing their skills and the benefits they will bring to the charity. All trustees are provided with the CIO governing document, a role description detailing their responsibilities, and Charity Commission and "Code of Good Governance" good practice guidelines. All appointees are invited to visit the charity's locations and meet with key staff and trustees prior to their application being formally considered by the board. The trustees are kept abreast of regulatory and general governance developments through internal communications, board presentations and other reference material.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1157147

Principal address

c/o Southampton General Hospital
Mailpoint 3
Tremona Road
Southampton
Hampshire
SO16 6YD

Trustees

R W Sutcliffe
Dr S U Flavell
Dr D J Flavell
Mrs J Sherborne
Mrs B Robinson-Grindey

Independent Examiner

Azets
Carnac Place
Cams Hall Estate
Fareham
Hampshire
PO16 8UY

Bankers

Nat West Bank PLC
12 High Street
Southampton
SO14 2BF

HSBC Bank PLC
55 Above Bar Street
Southampton
SO14 7DZ

Virgin Money
10 College Place
Southampton
Hampshire
SO15 6YD

LEUKAEMIA BUSTERS
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31ST MARCH 2021

REFERENCE AND ADMINISTRATIVE DETAILS

Patrons

David and Thorunn Gower

Officers

Dr D J Flavell (Charity & Scientific Director)

Dr S U Flavell (Executive Scientific Director)

Fundraising Presidents

Harry and Sandra Redknapp

Ambassadors

Stewart Dunn

Lawrie McMenemy

Bruce Parker

Sally Taylor

Approved by order of the board of trustees on 6 December 2021 and signed on its behalf by:



17/1/2022

R W Sutcliffe - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
LEUKAEMIA BUSTERS**

Independent examiner's report to the trustees of Leukaemia Busters

I report to the charity trustees on my examination of the accounts of Leukaemia Busters (the CIO) for the year ended 31st March 2021.

Responsibilities and basis of report

As the charity trustees of the CIO you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the CIO's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the CIO as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

J Reilly

J R Reilly ACCA
Azets
Carnac Place
Cams Hall Estate
Fareham
Hampshire
PO16 8UY

Date: 18/01/2022

LEUKAEMIA BUSTERS

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31ST MARCH 2021**

	Notes	Unrestricted fund £	Restricted fund £	2021 Total funds £	2020 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	183,114	4,750	187,864	55,069
Charitable activities					
Leukaemia research		-	-	-	-
Other trading activities	3	4,125	-	4,125	10,549
Grant income		81,895		81,895	2,080
Investment income	4	2,860	-	2,860	3,472
Total		271,994	4,750	276,744	71,170
EXPENDITURE ON					
Raising funds		2,213	323	2,536	3,146
Charitable activities					
Leukaemia research		97,465	4,750	102,215	102,798
Total		99,678	5,073	104,751	105,944
NET INCOME/(EXPENDITURE)		172,316	(323)	171,993	(34,774)
Transfers between funds	12	-	-	-	-
Net movement in funds		172,316	(323)	171,993	(34,774)
RECONCILIATION OF FUNDS					
Total funds brought forward		255,158	323	255,481	290,255
TOTAL FUNDS CARRIED FORWARD		<u>427,474</u>	<u>-</u>	<u>427,474</u>	<u>255,481</u>

The notes form part of these financial statements

LEUKAEMIA BUSTERS


BALANCE SHEET 31ST MARCH 2021

	Notes	Unrestricted fund £	Restricted fund £	2021 Total funds £	2020 Total funds £
FIXED ASSETS					
Tangible assets	10	286	-	286	2,261
CURRENT ASSETS					
Debtors		86	-	86	2,080
Cash in hand		433,274	-	433,274	255,132
		<u>433,360</u>	<u>-</u>	<u>433,360</u>	<u>257,212</u>
CREDITORS					
Amounts falling due within one year	11	(6,172)	-	(6,172)	(3,992)
NET CURRENT ASSETS		<u>427,188</u>	<u>-</u>	<u>427,188</u>	<u>253,220</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>427,474</u>	<u>-</u>	<u>427,474</u>	<u>255,481</u>
NET ASSETS		<u>427,474</u>	<u>-</u>	<u>427,474</u>	<u>255,481</u>
FUNDS	12				
Unrestricted funds				427,474	255,158
Restricted funds				-	323
TOTAL FUNDS				<u>427,474</u>	<u>255,481</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 6 December 2021 and were signed on its behalf by:

 17/1/2022

R W Sutcliffe - Trustee

 17/1/2022

S U Flavell - Trustee

The notes form part of these financial statements

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Raising funds

Fund raising costs

Fund raising costs represent promotional expenses incurred by the trust.

Promotional items

Promotional items are written off in the year of purchase

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2021

2. DONATIONS AND LEGACIES

	2021 £	2020 £
Friendship scheme	8,720	6,817
In memoriam/bequests	11,043	8,324
Donations	30,649	39,428
Grant making trusts	-	500
Legacy income	137,452	-
Total	187,864	55,069

Summary of legacy income

	2021 £	2020 £
The late Pamela Barnes	126,032	-
The late Mrs Taylor	10,000	-
The late Mrs Gardner	1,000	-
The late Mrs Dakin	420	-
	137,452	-

3. OTHER TRADING ACTIVITIES

	2021 £	2020 £
Eastleigh Fire Station open day	-	1,493
Pelhams Plunge Swimathon	-	766
Den Humby Memorial Darts Match	-	766
East Drayton football match	-	436
RJ Memorial Golf day	-	2,184
Andy Pillar 40 Marathons in 52 weeks	3990	3,075
Skydive	135	1,829
Total	4,125	10,549

4. INVESTMENT INCOME

	2021 £	2020 £
Deposit account interest	2,860	3,472

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2021

5. TRUSTEES' REMUNERATION AND BENEFITS

Two trustees were employed by the charity to manage its scientific research programme for the period ended 31st March 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31st March 2021 nor for the year ended 31st March 2020.

6. STAFF COSTS

The average monthly number of employees during the year was as follows:

	2021	2020
Scientific staff	<u>4</u>	<u>5</u>

No employees received emoluments in excess of £60,000.

7. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted fund £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	55,069	-	55,069
Leukaemia Research	-	-	-
Other trading activities	10,549	-	10,549
Grant income	2,080	-	2,080
Investment income	<u>3,472</u>	<u>-</u>	<u>3,472</u>
Total	71,170	-	71,170
EXPENDITURE ON			
Raising funds	3,146	-	3,146
Charitable activities			
Leukaemia research	<u>100,575</u>	<u>2,223</u>	<u>102,798</u>
Total	<u>103,721</u>	<u>2,223</u>	<u>105,944</u>
NET INCOME/(EXPENDITURE)	(32,551)	(2,223)	(34,774)
Transfers between funds	<u>-</u>	<u>-</u>	<u>-</u>
Net movement in funds	(32,551)	(2,223)	(34,774)
RECONCILIATION OF FUNDS			
Total funds brought forward	287,709	2,546	290,255
TOTAL FUNDS CARRIED FORWARD	<u>255,158</u>	<u>323</u>	<u>255,481</u>

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2021

8. DONATION FROM LEUKAEMIA BUSTERS

During the period a donation of £335.95 was received from Leukaemia Busters Charity Number 1010957.

9. RESTRICTED FUND

The restricted fund includes the following:

Fixed assets

These have been written down in line with the accounting policy.

10. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1st April 2020	40,331
Additions	97
	<hr/>
At 31st March 2021	40,428
DEPRECIATION	
At 1st April 2020	38,070
Charge for year	2,072
	<hr/>
At 31st March 2021	40,142
NET BOOK VALUE	
At 31st March 2021	286
	<hr/>
At 31st March 2020	2,261
	<hr/>

LEUKAEMIA BUSTERS

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST MARCH 2021**

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Trade creditors	1,053	119
Taxation and social security	1,815	1,211
Other creditors	3,304	2,661
	<u>6,172</u>	<u>3,992</u>

12. MOVEMENT IN FUNDS

	At 1/4/20 £	Net movement in funds £	Transfers between funds £	At 31/3/21 £
Unrestricted funds				
General fund	255,158	172,316	-	427,474
Restricted funds				
Restricted fund	323	(323)	-	-
	<u>255,481</u>	<u>171,993</u>	<u>-</u>	<u>427,474</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	271,995	(99,678)	172,317
Restricted funds			
Restricted fund	4,750	(5,073)	(323)
	<u>276,745</u>	<u>(104,751)</u>	<u>171,994</u>

Comparatives for movement in funds

	At 1/4/19 £	Net movement in funds £	Transfers between funds £	At 31/3/20 £
Unrestricted funds				
General fund	287,709	(32,551)	-	255,158
Restricted funds				
Restricted fund	2,546	(2,223)	-	323
	<u>290,255</u>	<u>(34,774)</u>	<u>-</u>	<u>255,481</u>

LEUKAEMIA BUSTERS

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31ST MARCH 2021

12. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	71,170	(103,721)	(32,551)
Restricted funds			
Restricted fund	-	(2,223)	(2,223)
	<hr/>	<hr/>	<hr/>
TOTAL FUNDS	<u>71,170</u>	<u>(105,944)</u>	<u>(34,774)</u>

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31st March 2021 other than the donation from Leukaemia Busters mentioned above.